Hepatocellular carcinoma is the most common form of primary liver cancer, and globally it is the sixth most common cancer. In this study, we use liposomes that can co-encapsulate the therapeutic agent (oxaliplatin or gemcitabine) in addition to iron oxide nanoparticles to enable MRI-monitored local delivery of the therapeutic agent to limit proangiogenic responses in non-resectable liver tumors following transcatheter embolotherapies. The results showed increased R2* values in the tumor regions at one week post-infusion, compared to the surrounding liver parenchyma and to same regions immediately after infusion, which allows for confirmation of procedural success and proper catheter-selective tumor targeting.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords